Keyword :   immunotherapy

New therapeutic options in the treatment of patients with relapsed/refractory B-cell acute lymphoblastic leukemia
Дата: 2024-04-11
Immunological markers of dendritic cell vaccine response in glioblastoma patients
Authors: Skachkova O.V. Glavatskyi O.Ya. Zemskova O.V. Gorbach O.I.... Дата: 2024-04-08
Expanding the role of immuno-oncology treatment in the management of patients with melanoma or triple-negative breast cancer
Т. 13, №4 (52)
Modern approaches to the diagnosis and treatment of lymphoproliferative diseases
Дата: 2023-12-06
Prospects for the use of pembrolizumab in the treatment of previously untreated patients with advanced malignant pleural mesothelioma
Author:Nemish I.L. Т. 13, № 3 (51)
The value of the immunotherapy of alfa/beta defensins in the development of epitheliitis in patients with oropharyngeal cancer
Authors: Hirna H.A. Kostyshyn I.D. Rozhko M.M. Lukach Ye.V.... Т. 11, № 3-4 (43-44)
World Conference on Lung Cancer 2020: new in the treatment of advanced/metastatic NSCLC
Т. 11, № 1-2 (41-42)
Five-year overall survival and progression-free survival of patients with advanced NSCLC receiving pembrolizumab
T. 10, № 3-4 (39-40)
The first experience of using dendritic cells immunotherapy in complex treatment of patients with glioblastoma in Ukraine
Authors: Khranovska N.M. Skachkova O.V. Gorbach O.I. Zhukova V.M.... Т. 9, № 2 (34) 2019
Immunotherapy in the treatment of melanoma patients: current state of the problem
Authors: Kukushkina M.M. Korovin S.I. Lytvynenko B.V. Т. 8, № 4 (32) 2018
Capabilities of immunotherapy of metastasis of melanoma B16 in C57Bl/6 mice with transfer factor
Authors: Fil’chakov F.V. Lоn A.D. Shumilina К.S. Kukushkina S.М.... Т. 8, № 2 (30) 2018
Immunotherapy is the first line of advanced lung cancer: what is new in 2018
Authors: Ryspayeva D.E. Ponomarova O.V. Lisovska N.Y. Т. 8, № 2 (30) 2018
Immunotherapy of Hodgkin’s lymphoma: a new treatment strategy
Author:Kryachok I. Т. 8, № 2 (30) 2018
The deficiency of natural killer cells and/or natural killer T cells as the cause of malignancies in humans
Authors: Maltsev D.V. Hirna H.A. Т. 8, № 1 (29) 2018
A clinical case of treating of a patient with melanoma using checkpoint inhibitor pembolizumab (anti-PD-1 monoclonal antibody)
Author:Kosinova V.G. №4(28) 2017

1234